Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody approved for Hodgkin's lymphoma (HL) in the pediatric population, induces sensory neuropathy. The gene discussed is TNFRSF8; the disease is sensory peripheral neuropathy.